PTC Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
PTC Therapeutics, Inc. (PTCT) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$2.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-07-30
- PTC Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$2.45M, a 111.49% decline year-over-year.
- PTC Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$2.04M, a 117.05% decline year-over-year.
- PTC Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $4.57M.
- PTC Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$1.43M, a 111.73% decline year-over-year.
- PTC Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $36.39M.
- PTC Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$24.60M.
- PTC Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was -$6.08M, a 120.91% decline from fiscal 2022.
- PTC Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was $29.08M, a 20.71% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$2.45M 10-Q · filed 2026-07-30 | -$4.48M 10-Q · filed 2026-07-30 | $87.00K derived: sum of 3 quarters · filed 2026-07-30 | -$1.34M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | -$2.04M 10-Q · filed 2026-05-07 | $2.54M derived: sum of 2 quarters · filed 2026-05-07 | $1.11M derived: sum of 3 quarters · filed 2026-05-07 | $22.41M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $4.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.15M derived: sum of 2 quarters · filed 2026-02-19 | $24.45M derived: sum of 3 quarters · filed 2026-07-30 | $36.39M 10-K · filed 2026-02-19 | |
| 2025-09-30 | -$1.43M 10-Q · filed 2025-11-04 | $19.88M derived: sum of 2 quarters · filed 2026-07-30 | $31.82M 10-Q · filed 2025-11-04 | $10.27M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $21.30M 10-Q · filed 2026-07-30 | $33.24M 10-Q · filed 2026-07-30 | $11.70M derived: sum of 3 quarters · filed 2026-07-30 | $23.85M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | $11.94M 10-Q · filed 2026-05-07 | -$9.61M derived: sum of 2 quarters · filed 2026-05-07 | $2.55M derived: sum of 3 quarters · filed 2026-05-07 | -$8.39M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$21.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$9.39M derived: sum of 2 quarters · filed 2026-02-19 | -$20.33M derived: sum of 3 quarters · filed 2026-02-19 | -$24.60M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $12.15M 10-Q · filed 2025-11-04 | $1.22M derived: sum of 2 quarters · filed 2025-11-04 | -$3.06M 10-Q · filed 2025-11-04 | -$13.95M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-06-30 | -$10.94M 10-Q · filed 2025-08-07 | -$15.21M 10-Q · filed 2025-08-07 | -$26.11M derived: sum of 3 quarters · filed 2026-02-19 | -$15.07M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-03-31 | -$4.28M 10-Q · filed 2025-05-06 | -$15.17M derived: sum of 2 quarters · filed 2026-02-19 | -$4.13M derived: sum of 3 quarters · filed 2026-02-19 | -$3.97M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2023-12-31 | -$10.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $146.00K derived: sum of 2 quarters · filed 2026-02-19 | $302.00K derived: sum of 3 quarters · filed 2026-02-19 | -$6.08M 10-K · filed 2026-02-19 | |
| 2023-09-30 | $11.04M 10-Q · filed 2024-11-07 | $11.20M derived: sum of 2 quarters · filed 2024-11-07 | $4.81M 10-Q · filed 2024-11-07 | -$26.60M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $156.00K 10-Q · filed 2024-08-08 | -$6.23M 10-Q · filed 2024-08-08 | -$37.64M derived: sum of 3 quarters · filed 2025-02-27 | -$11.68M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | -$6.38M 10-Q · filed 2024-04-25 | -$37.79M derived: sum of 2 quarters · filed 2025-02-27 | -$11.84M derived: sum of 3 quarters · filed 2025-02-27 | $17.02M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | -$31.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$5.46M derived: sum of 2 quarters · filed 2025-02-27 | $23.40M derived: sum of 3 quarters · filed 2025-02-27 | $29.08M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $25.95M 10-Q · filed 2023-10-26 | $54.81M derived: sum of 2 quarters · filed 2023-10-26 | $60.49M 10-Q · filed 2023-10-26 | $69.17M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $28.86M 10-Q · filed 2023-08-03 | $34.53M 10-Q · filed 2023-08-03 | $43.21M derived: sum of 3 quarters · filed 2024-02-29 | $56.34M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | $5.67M 10-Q · filed 2023-04-27 | $14.35M derived: sum of 2 quarters · filed 2024-02-29 | $27.48M derived: sum of 3 quarters · filed 2024-02-29 | $20.14M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $8.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $21.80M derived: sum of 2 quarters · filed 2024-02-29 | $14.46M derived: sum of 3 quarters · filed 2024-02-29 | $36.67M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $13.13M 10-Q · filed 2022-10-27 | $5.78M derived: sum of 2 quarters · filed 2022-10-27 | $28.00M 10-Q · filed 2022-10-27 | $2.77M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-06-30 | -$7.34M 10-Q · filed 2022-08-04 | $14.87M 10-Q · filed 2022-08-04 | -$10.36M derived: sum of 3 quarters · filed 2023-02-21 | -$36.07M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-03-31 | $22.21M 10-Q · filed 2022-05-03 | -$3.02M derived: sum of 2 quarters · filed 2023-02-21 | -$28.73M derived: sum of 3 quarters · filed 2023-02-21 | -$36.76M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2020-12-31 | -$25.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | -$50.94M derived: sum of 2 quarters · filed 2023-02-21 | -$58.97M derived: sum of 3 quarters · filed 2023-02-21 | -$50.37M 10-K · filed 2023-02-21 | |
| 2020-09-30 | -$25.71M 10-Q · filed 2021-10-28 | -$33.74M derived: sum of 2 quarters · filed 2021-10-28 | -$25.14M 10-Q · filed 2021-10-28 | -$36.34M derived: sum of 4 quarters · filed 2022-02-22 | |
| 2020-06-30 | -$8.03M 10-Q · filed 2021-07-29 | $568.00K 10-Q · filed 2021-07-29 | -$10.63M derived: sum of 3 quarters · filed 2022-02-22 | -$11.94M derived: sum of 4 quarters · filed 2022-02-22 | |
| 2020-03-31 | $8.60M 10-Q · filed 2021-05-04 | -$2.60M derived: sum of 2 quarters · filed 2022-02-22 | -$3.91M derived: sum of 3 quarters · filed 2022-02-22 | -$2.79M derived: sum of 4 quarters · filed 2022-02-22 | |
| 2019-12-31 | -$11.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | -$12.51M derived: sum of 2 quarters · filed 2022-02-22 | -$11.39M derived: sum of 3 quarters · filed 2022-02-22 | -$12.05M 10-K · filed 2022-02-22 | |
| 2019-09-30 | -$1.31M 10-Q · filed 2020-10-29 | -$189.00K derived: sum of 2 quarters · filed 2020-10-29 | -$846.00K 10-Q · filed 2020-10-29 | -$1.01M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $1.12M 10-Q · filed 2020-08-05 | $460.00K 10-Q · filed 2020-08-05 | $294.00K derived: sum of 3 quarters · filed 2021-02-25 | $67.00K derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$657.00K 10-Q · filed 2020-04-30 | -$823.00K derived: sum of 2 quarters · filed 2021-02-25 | -$1.05M derived: sum of 3 quarters · filed 2021-02-25 | -$4.15M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | -$166.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$393.00K derived: sum of 2 quarters · filed 2021-02-25 | -$3.49M derived: sum of 3 quarters · filed 2021-02-25 | -$2.51M 10-K · filed 2021-02-25 | |
| 2018-09-30 | -$227.00K 10-Q · filed 2019-10-30 | -$3.33M derived: sum of 2 quarters · filed 2019-10-30 | -$2.34M 10-Q · filed 2019-10-30 | ||
| 2018-06-30 | -$3.10M 10-Q · filed 2019-08-06 | -$2.11M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | $984.00K 10-Q · filed 2019-05-02 | ||||
| 2017-12-31 | $5.45M 10-K · filed 2020-03-02 | ||||
| 2016-12-31 | -$285.00K 10-K · filed 2019-03-01 | ||||
| 2015-12-31 | -$463.00K 10-K · filed 2018-03-06 | ||||
| 2014-12-31 | -$807.00K 10-K · filed 2017-03-16 | -$807.06K 10-K · filed 2015-03-02 | |||
| 2013-12-31 | $70.00K 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |